PE20080181A1 - Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer - Google Patents
Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimerInfo
- Publication number
- PE20080181A1 PE20080181A1 PE2007000354A PE2007000354A PE20080181A1 PE 20080181 A1 PE20080181 A1 PE 20080181A1 PE 2007000354 A PE2007000354 A PE 2007000354A PE 2007000354 A PE2007000354 A PE 2007000354A PE 20080181 A1 PE20080181 A1 PE 20080181A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- beta
- peptide
- alzheimer
- treatment
- Prior art date
Links
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 abstract 1
- 101710176384 Peptide 1 Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A UN ANTICUERPO QUE COMPRENDE LAS SIGUIENTES CDR: CDRH1: SEC ID N0:1; CDRH2: SEC ID N0: 2; CDRH3: SEC ID N0:3; SEC ID N0: 3DENTRO DE UNA REGION VARIABLE DE CADENA PESADA HUMANA PROCEDENTE DE LA FAMILIA GENICA VH3 Y CDRL1: SEC ID N0:4; CDRL2: SEC ID N0:5; CDRL3: SEC ID N0: 6 DENTRO DE UNA REGION VARIABLE DE CADENA LIGERA HUMANA PROCEDENTE DE LA SECUENCIA DE AMINOACIDOS DESCRITA EN GENPEPT SEC ID N0:24. EL ANTICUERPO SE UNE AL PEPTIDO BETA-AMILIODE 1-12 CON UNA CONSTANTE DE EQUILIBRIO KD MENOR DE 100 pM Y TIENE UNA CONSTANTE DE EQUILIBRIO KD PARA LA UNION AL PEPTIDO BETA-AMILIODE 2-13 QUE SE 1000 VECES MAYOR QUE LA DEL PEPTIDO 1-12. DICHO ANTICUERPO ES UN ISOTOPO IgG1 UTIL EN EL TRATAMIENTO DE ALZHEIMER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78758806P | 2006-03-30 | 2006-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080181A1 true PE20080181A1 (es) | 2008-03-16 |
Family
ID=38284050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000354A PE20080181A1 (es) | 2006-03-30 | 2007-03-28 | Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US8227576B2 (es) |
| EP (2) | EP2177536B1 (es) |
| JP (1) | JP5103466B2 (es) |
| KR (2) | KR20120093400A (es) |
| CN (2) | CN101415729B (es) |
| AR (1) | AR060332A1 (es) |
| AT (1) | ATE451392T1 (es) |
| AU (1) | AU2007233831B2 (es) |
| BR (1) | BRPI0709246A2 (es) |
| CA (1) | CA2647808C (es) |
| CR (1) | CR10347A (es) |
| CY (1) | CY1109877T1 (es) |
| DE (1) | DE602007003703D1 (es) |
| DK (2) | DK1996621T3 (es) |
| EA (1) | EA015654B9 (es) |
| ES (2) | ES2338179T3 (es) |
| HR (2) | HRP20100115T1 (es) |
| IL (1) | IL193695A (es) |
| JO (1) | JO2576B1 (es) |
| MA (1) | MA30337B1 (es) |
| MX (1) | MX2008012483A (es) |
| MY (1) | MY149630A (es) |
| NO (1) | NO20083793L (es) |
| NZ (1) | NZ571038A (es) |
| PE (1) | PE20080181A1 (es) |
| PL (2) | PL2177536T3 (es) |
| PT (2) | PT2177536E (es) |
| SI (2) | SI1996621T1 (es) |
| TW (1) | TWI385179B (es) |
| UA (1) | UA94734C2 (es) |
| WO (1) | WO2007113172A2 (es) |
| ZA (1) | ZA200807911B (es) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| CA2516056C (en) | 2003-01-06 | 2012-05-29 | Angiochem Inc. | Aprotinin and analogs as carriers across the blood-brain barrier |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| JP2008523815A (ja) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのヒト化アミロイドβ抗体 |
| US7906625B2 (en) | 2005-01-24 | 2011-03-15 | Amgen Inc. | Humanized anti-amyloid antibody |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| CN117903302A (zh) | 2005-11-30 | 2024-04-19 | Abbvie 公司 | 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法 |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| EP2046833B9 (en) | 2006-07-14 | 2014-02-19 | AC Immune S.A. | Humanized antibody against amyloid beta |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2486928A1 (en) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| US7931899B2 (en) | 2007-05-14 | 2011-04-26 | Medtronic, Inc | Humanized anti-amyloid beta antibodies |
| US8323654B2 (en) | 2007-05-14 | 2012-12-04 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| SI2182983T1 (sl) * | 2007-07-27 | 2014-09-30 | Janssen Alzheimer Immunotherapy | Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta |
| CN101848936B (zh) * | 2007-08-20 | 2017-05-03 | 葛兰素集团有限公司 | 生产方法 |
| GB0718737D0 (en) * | 2007-09-25 | 2007-11-07 | Glaxo Group Ltd | Antibodies |
| EP2238166B1 (en) | 2007-10-05 | 2013-11-27 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
| AU2008311365B2 (en) * | 2007-10-05 | 2015-03-12 | Ac Immune S.A. | Humanized antibody |
| MX2010003622A (es) | 2007-10-12 | 2010-04-14 | Hoffmann La Roche | Expresion proteinica a partir de acidos nucleicos multiples. |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| WO2009070648A2 (en) * | 2007-11-27 | 2009-06-04 | Medtronic, Inc. | Humanized anti-amyloid beta antibodies |
| BRPI0819916A2 (pt) * | 2007-12-11 | 2015-05-19 | Glaxo Group Ltd | Proteína de ligação a antígeno, composição farmacêutica, método para tratar um paciente humano afligido com uma doença, anticorpo ou fragmento do mesmo, e, proteína de ligação a antígeno. |
| EP2235058A2 (en) * | 2007-12-21 | 2010-10-06 | Amgen, Inc | Anti-amyloid antibodies and uses thereof |
| CL2009001081A1 (es) | 2008-05-06 | 2010-09-24 | Glaxo Group Ltd | Procedimiento para producir un vehiculo en forma de particulas que comprende disolver polibutilcianoacrilado en un disolvente organico para formar una solucion polimerica, anadir una solucion acuosa, mezclar y obtener el vehiculo en forma de particulas; composicion farmaceutica que comprende dicho vehiculo. |
| MX2011004017A (es) | 2008-10-15 | 2011-06-24 | Angiochem Inc | Conjugados de agonistas glp-1 y usos de los mismos. |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| US9914754B2 (en) | 2008-12-05 | 2018-03-13 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| EP2421562B1 (en) | 2009-04-20 | 2019-03-13 | Angiochem Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
| JP5932642B2 (ja) * | 2009-07-02 | 2016-06-08 | アンジオケム インコーポレーテッド | 多量体ペプチドコンジュゲートおよびその使用 |
| EP2475428B1 (en) | 2009-09-11 | 2015-07-01 | Probiodrug AG | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| EP2308897A1 (en) * | 2009-10-09 | 2011-04-13 | Pierre Fabre Medicament | Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer |
| EA201201227A1 (ru) | 2010-03-03 | 2013-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Бипаратопные а-бета-связывающие полипептиды |
| MX360403B (es) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Proteinas de union a amiloide beta. |
| WO2011149461A1 (en) * | 2010-05-27 | 2011-12-01 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
| SG187173A1 (en) | 2010-07-30 | 2013-02-28 | Ac Immune Sa | Safe and functional humanized anti beta-amyloid antibody |
| EP2603524A1 (en) | 2010-08-14 | 2013-06-19 | AbbVie Inc. | Amyloid-beta binding proteins |
| EP3208282A1 (en) * | 2010-11-30 | 2017-08-23 | F. Hoffmann-La Roche AG | Low affinity anti transferrin receptor and their use to transfer therapeutic scfv across the blood brain barrier |
| US8703137B2 (en) | 2011-01-31 | 2014-04-22 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| RU2632647C2 (ru) | 2011-04-22 | 2017-10-06 | Аптево Рисерч Энд Девелопмент Ллс | Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы |
| GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| JP6419068B2 (ja) | 2012-05-21 | 2018-11-07 | ジェネンテック， インコーポレイテッド | 血液脳関門輸送の安全性を改善するための方法 |
| RU2509155C1 (ru) * | 2012-10-25 | 2014-03-10 | Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук | Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии |
| JP2016529482A (ja) | 2013-06-19 | 2016-09-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | 新規アッセイ |
| CN104558172A (zh) * | 2015-01-04 | 2015-04-29 | 东南大学 | 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用 |
| WO2016205367A1 (en) | 2015-06-15 | 2016-12-22 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| WO2017072090A1 (en) * | 2015-10-27 | 2017-05-04 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| KR20230164223A (ko) * | 2017-06-29 | 2023-12-01 | 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 아밀로이드 침착 질환의 치료를 위한 키메라 항체 |
| US11382974B2 (en) | 2017-08-01 | 2022-07-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of amyloid deposition diseases |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| US12018069B2 (en) | 2018-06-28 | 2024-06-25 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for imaging amyloid deposits |
| MX2021000235A (es) | 2018-07-17 | 2021-03-25 | Jiangsu Hengrui Medicine Co | Anticuerpo anti-abeta, fragmento de union a antigeno del mismo y aplicacion del mismo. |
| CN113874078B (zh) | 2019-04-05 | 2025-05-06 | Tauc3生物制品有限公司 | 抗tauc3抗体及其应用 |
| TW202216760A (zh) | 2020-07-23 | 2022-05-01 | 愛爾蘭商歐薩爾普羅席納有限公司 | 抗類澱粉β (ABETA)抗體 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| CN114591917B (zh) * | 2022-05-07 | 2022-09-02 | 北京第一生物化学药业有限公司 | 产生结合β-淀粉样蛋白的抗体的杂交瘤细胞及其用途 |
| CN114591918B (zh) * | 2022-05-07 | 2022-07-26 | 北京第一生物化学药业有限公司 | 产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途 |
| KR102530956B1 (ko) * | 2022-09-08 | 2023-05-11 | 주식회사 알츠코리아 | 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도 |
| CN118638219B (zh) * | 2024-08-19 | 2024-11-22 | 成都迈科康生物科技有限公司 | 一种抗轮状病毒vp8蛋白的抗体或其抗原结合片段、抗体偶联物、核酸、载体、细胞及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811517A (en) * | 1992-01-27 | 1998-09-22 | Icos Corporation | ICAM-related protein variants |
| EP2305709A1 (en) * | 1997-04-09 | 2011-04-06 | Intellect Neurosciences, Inc. | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods for use thereof |
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| EP1133699A1 (en) * | 1998-11-25 | 2001-09-19 | Scios Inc. | Prevention and treatment of amyloid-associated disorders |
| CN104341500A (zh) * | 2000-02-24 | 2015-02-11 | 华盛顿大学 | 螯合淀粉样蛋白β肽的人源化抗体 |
| US6787519B2 (en) * | 2000-11-03 | 2004-09-07 | The Regents Of The University Of California | Methods of treating disorders related to apoE |
| WO2004029629A1 (en) * | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
| ITTO20020867A1 (it) * | 2002-10-08 | 2004-04-09 | Pro Cord Spa | Schienale di sedia. |
| CA2501945A1 (en) * | 2002-10-09 | 2004-04-22 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
-
2007
- 2007-03-27 US US12/294,438 patent/US8227576B2/en not_active Expired - Fee Related
- 2007-03-27 JP JP2009502072A patent/JP5103466B2/ja not_active Expired - Fee Related
- 2007-03-27 NZ NZ571038A patent/NZ571038A/en not_active IP Right Cessation
- 2007-03-27 MX MX2008012483A patent/MX2008012483A/es active IP Right Grant
- 2007-03-27 SI SI200730173T patent/SI1996621T1/sl unknown
- 2007-03-27 WO PCT/EP2007/052928 patent/WO2007113172A2/en not_active Ceased
- 2007-03-27 EP EP09178407.4A patent/EP2177536B1/en active Active
- 2007-03-27 PT PT91784074T patent/PT2177536E/pt unknown
- 2007-03-27 AT AT07727401T patent/ATE451392T1/de active
- 2007-03-27 ES ES07727401T patent/ES2338179T3/es active Active
- 2007-03-27 CN CN2007800124360A patent/CN101415729B/zh not_active Expired - Fee Related
- 2007-03-27 PL PL09178407T patent/PL2177536T3/pl unknown
- 2007-03-27 EP EP07727401A patent/EP1996621B1/en active Active
- 2007-03-27 DE DE602007003703T patent/DE602007003703D1/de active Active
- 2007-03-27 EA EA200801842A patent/EA015654B9/ru not_active IP Right Cessation
- 2007-03-27 BR BRPI0709246-6A patent/BRPI0709246A2/pt not_active IP Right Cessation
- 2007-03-27 UA UAA200810923A patent/UA94734C2/ru unknown
- 2007-03-27 SI SI200731503T patent/SI2177536T1/sl unknown
- 2007-03-27 DK DK07727401.7T patent/DK1996621T3/da active
- 2007-03-27 KR KR1020127016745A patent/KR20120093400A/ko not_active Withdrawn
- 2007-03-27 CN CN201310338011.6A patent/CN103539857A/zh active Pending
- 2007-03-27 CA CA2647808A patent/CA2647808C/en not_active Expired - Fee Related
- 2007-03-27 ES ES09178407.4T patent/ES2484967T3/es active Active
- 2007-03-27 KR KR1020087026640A patent/KR101263294B1/ko not_active Expired - Fee Related
- 2007-03-27 AU AU2007233831A patent/AU2007233831B2/en not_active Ceased
- 2007-03-27 HR HR20100115T patent/HRP20100115T1/hr unknown
- 2007-03-27 DK DK09178407.4T patent/DK2177536T3/da active
- 2007-03-27 PT PT07727401T patent/PT1996621E/pt unknown
- 2007-03-27 PL PL07727401T patent/PL1996621T3/pl unknown
- 2007-03-28 JO JO200788A patent/JO2576B1/en active
- 2007-03-28 PE PE2007000354A patent/PE20080181A1/es not_active Application Discontinuation
- 2007-03-28 TW TW096110663A patent/TWI385179B/zh not_active IP Right Cessation
- 2007-03-28 AR ARP070101295A patent/AR060332A1/es not_active Application Discontinuation
-
2008
- 2008-08-26 IL IL193695A patent/IL193695A/en not_active IP Right Cessation
- 2008-09-03 NO NO20083793A patent/NO20083793L/no not_active Application Discontinuation
- 2008-09-15 ZA ZA200807911A patent/ZA200807911B/xx unknown
- 2008-09-26 MY MYPI20083843A patent/MY149630A/en unknown
- 2008-10-07 CR CR10347A patent/CR10347A/es unknown
- 2008-10-15 MA MA31293A patent/MA30337B1/fr unknown
-
2010
- 2010-03-01 CY CY20101100198T patent/CY1109877T1/el unknown
-
2012
- 2012-06-08 US US13/491,810 patent/US9193784B2/en not_active Expired - Fee Related
-
2014
- 2014-06-30 HR HRP20140618TT patent/HRP20140618T1/hr unknown
-
2015
- 2015-10-13 US US14/881,428 patent/US20160024197A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080181A1 (es) | Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| CL2013003140A1 (es) | Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene. | |
| JP2020500538A5 (es) | ||
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| RU2747735C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| AR068723A1 (es) | Proteina que se une a antigenos que se une a il-23 humana y sus usos | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| PE20120554A1 (es) | Polipeptidos y metodo de tratamiento | |
| NZ603972A (en) | Anti-fgfr2 antibodies | |
| HRP20170882T1 (hr) | Humani antigen-vezujući proteini koji se vežu za beta-klotho, fgf receptore i njihove komplekse | |
| ES2571129T3 (es) | Anticuerpos anti-CTLA4 humanizados | |
| RU2014146503A (ru) | Белки, связывающие антиген - лиганд cd30 человека | |
| PE20131400A1 (es) | Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9) | |
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| PE20161033A1 (es) | Proteinas de union al antigeno gitr | |
| PE20080214A1 (es) | Moleculas de anticuerpo que se unen a la il-17 humana | |
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| PE20090768A1 (es) | Metodos y composiciones para el tratamiento de enfermedades alergicas | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
| ES2570853T3 (es) | Moléculas de anticuerpo humanizadas específicas para IL-31 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |